

Table 1. Lymph node FNA cohort demographics and baseline clinical characteristics

	Healthy	Kidney Transplant Recipients
Variable	Total N=15	Total N=10
	N (%)	N (%)
Age (Median [Range])	34 [23-76]	52 [28-66]
Sex		
Males	6 (40)	7 (70)
Females	9 (60)	3 (30)
Race		
African American	0 (0)	5 (50)
Asian	5 (33.3)	1 (10)
White	10 (66.7)	4 (40)
Other	0 (0)	0 (0)
Ethnicity		
Not of Hispanic, Latinx, or Spanish origin	14 (93.3)	9 (90)
Hispanic, Latinx, or Spanish origin	1 (6.7)	1 (10)
Etiology of Renal Failure		T2DM (4), HTN (1), PCKD (3), FSGS (1), Lupus (1)
Duration of Dialysis (Months), (Median [Range])		49.3 [0-107.5]
Time since Kidney Transplant (Months), (Median [Range])^a		12.6 [-0.3 - 63.1]
Type of donor organ		DDKT (8), LUKT (2)
Number of previous transplants (Mean [Range])		0 [0-0]
cPRA (%) (Median [Range])		0 [0-39]
eGFR (mL/min/1.73m²), (Median [Range])^{a, b}		51.5 [10 - >60]
WBC (tho/uL), (Median [Range])		5.9 [3.4-11.1]
ALC (tho/uL), (Median [Range])		0.5 [0-1.6]
Hgb (g/dL), (Median [Range])		11.6 [8.7-15.8]
Creatinine (mg/dL), (Median [Range])		1.63 [0.93-8.74]
Immunosuppression		
Thymoglobulin <1 yr. Prior ("n", Median [Range in days]) ^a		6, 57 [-11 - 158]

Thymoglobulin >1 yr. Prior ("n", Median [Range in days])		4, 1118 [1156-1883]
Maintenance		
Tacrolimus, Mycophenolate mofetil, Prednisone		8
Cyclosporine, Prednisone		1
History of SARS-CoV2 infection	0 (0)	1 (10)
Vaccine	BNT162b2 (10), mRNA-1273 (5)	BNT162b2 (9), mRNA-1273 (1)

^a One patient received the 1st dose of vaccination 9 days prior to transplant.

^b A value of 61 was used for any eGFR >60 for calculation of the median.

T2DM - Type 2 diabetes mellitus, HTN - hypertension, PCKD - polycystic kidney disease, FSGS - focal segmental glomerular sclerosis, DDKT - Deceased donor kidney transplant, LURT - Living unrelated kidney transplant, cPRA – Calculated panel-reactive antibody, eGFR – Estimated glomerular filtration rate, WBC – White blood cell count, ALC – Absolute lymphocyte count, Hgb - Hemoglobin.

Table 2. T cell AIM cohort demographics and baseline clinical characteristics

	Healthy	Kidney Transplant Recipients
Variable	Total N=11	Total N=10
	N (%)	N (%)
Age (Median [Range])	33 [23-62]	56 [28-70]
Sex		
Males	3 (27.3)	4 (40)
Females	8 (72.7)	6 (60)
Race		
African American	0 (0)	7 (70)
Asian	2 (18.2)	1 (10)
White	9 (81.8)	2 (20)
Other	0 (0)	0 (0)
Ethnicity		
Not of Hispanic, Latinx, or Spanish origin	10 (90.9)	10 (100)
Hispanic, Latinx, or Spanish origin	1 (9.1)	0 (0)
Etiology of Renal Failure		T2DM (3), HTN (2), T2DM/HTN (1), PCKD (3), FSGS (1)
Duration of Dialysis (Months), (Median [Range])		49.3 [0-107.5]
Time since Kidney Transplant (Months), (Median [Range])^a		12.6 [1.1 - 63.1]
Type of donor organ		DDKT (8), LUKT (2)
Number of previous transplants (Mean [Range])		0 [0-0]
cPRA (%) (Median [Range])		0 [0-39]
eGFR (mL/min/1.73m²), (Median [Range])^{a, b}		48 [35 - >60]
WBC (tho/uL), (Median [Range])		5.9 [2.8-11.1]
ALC (tho/uL), (Median [Range])		0.6 [0.2-2.3]
Hgb (g/dL), (Median [Range])		11.6 [8.7-13.4]
Creatinine (mg/dL), (Median [Range])		1.52 [0.8-2.05]
Immunosuppression		

Thymoglobulin <1 yr. Prior ("n", Median [Range in days]) ^a		5, 62 [31 - 158]
Thymoglobulin >1 yr. Prior ("n", Median [Range in days])		5, 1270 [1118-1883]
Maintenance		
Tacrolimus, Mycophenolate mofetil, Prednisone		7
Cyclosporine, Prednisone		3
History of SARS-CoV2 infection	0 (0)	0 (0)
Vaccine	BNT162b2 (8), mRNA-1273 (3)	BNT162b2 (9), mRNA-1273 (1)

^a A value of 61 was used for any eGFR >60 for calculation of the median. T2DM - Type 2 diabetes mellitus, HTN - hypertension, PCKD - polycystic kidney disease, FSGS - focal segmental glomerular sclerosis, DDKT - Deceased donor kidney transplant, LURT - Living unrelated kidney transplant, cPRA – Calculated panel-reactive antibody, eGFR – Estimated glomerular filtration rate, WBC – White blood cell count, ALC – Absolute lymphocyte count, Hgb - Hemoglobin.

Table 3. Flow Cytometry Panel for FNA Analysis, related to Figures 1-5 and Figures S1-4.

Antibody/Conjugate	Conjugation	Dilution Factor	Clone
CXCR5	BUV395	1:40	RF8B2
IgM	BUV496	1:200	UCH-B1
CD4	BUV563	1:200	SK3
CD11c	BUV661	1:100	B-ly6
IgD	BUV737	1:200	IA6-2
CD45RA	BUV805	1:200	HI100
Full S Probe	BV421	1:200	N/A
CCR6	BV480	1:33	11A9
CXCR3	BV510	1:20	G025H7
CD138	BV605	1:50	MI15
ICOS	BV650	1:50	C398.4A
CD20	BV750	1:200	2H7
CD38	BV785	1:100	III 155
HA Probe	Alexa Fluor 488	1:200	N/A
CD8	PerCP-eFluor 710	1:200	OKT-8
RBD Probe	PE	1:200	N/A
CCR4	PE-CF594	1:20	1G1
CD27	PE-Cy5	1:50	O323
CD19	PE-Cy5.5	1:200	SJ25C1
PD-1	PE-Cy7	1:50	EH12.2H7
Bcl6	Alexa Fluor 647	1:50	K112-91
CD11b	Alexa Fluor 700	1:100	ICRF44
Live/Dead	eFluor 780	1:2000	N/A

Table 4. Flow Cytometry Panel for Activation Induced Marker (AIM) analysis, related to Figure 6 and Figure S5.

Antibody/Conjugate	Conjugation	Dilution Factor	Clone
CD4	BUV395	1:400	SK3
CD8	BUV496	1:400	RPA-T8
CD45RA	BUV615	1:2000	HI100
CD27	BUV737	1:400	L128
CD3	BUV805	1:800	UCHT1
CXCR3	BV421	1:800	G02587
CCR7	BV650	1:400	G043H7
CD69	BV605	1:400	FN50
CD40L	BV711	1:50	24-31
CD107a	BV785	1:100	H4A3
IFN γ	FITC	1:400	4S.B3
CD200	PE	1:100	A18042B (OX2)
OX40	PE-Cy7	1:1600	Ber-ACT35
41BB	AF647	1:400	4B4-1
CXCR5	APC R700	1:100	RF8B2
CCR6	APC-Cy7	1:800	G034E3
Live/Dead	Ghost Dye Violet 510	1:800	N/A